Brief: MiNK Therapeutics Announces Clinical Data Of Allogeneic Inkt Cells (Agent-797) In Solid Tumor Cancers
18/04/2023 22:43
April 18 (Reuters) - Mink Therapeutics Inc INKT.O :
* MINK THERAPEUTICS ANNOUNCES CLINICAL DATA OF ALLOGENEIC
INKT
CELLS (AGENT-797) IN SOLID TUMOR CANCERS AT AACR ANNUAL MEETING
Source text for Eikon: ID:nGNX5MKcCS
Further company coverage: INKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mink Therapeutics
See all newsMiNK Therapeutics Q2 loss narrows on expense discipline
Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's